Source link : https://www.newshealth.biz/health-news/hypothalamic-obesity-tx-weekly-insulin-under-review-ozempic-price-investigation/
Setmelanotide, an investigational melanocortin-4 receptor agonist, reduced body mass index (BMI) by a mean 15% at 16 weeks and 26% at 12 months in people with hypothalamic obesity in a phase II open-label trial. Developer Rhythm Pharmaceuticals said phase III results are expected in the first half of 2025. (Lancet Diabetes & Endocrinology) The 1.7-mg […]
Author : News Health
Publish date : 2024-04-30 17:41:59
Copyright for syndicated content belongs to the linked Source.